Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2008-07-01
2008-07-01
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093100, C435S235100, C435S236000, C435S239000
Reexamination Certificate
active
07393527
ABSTRACT:
A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103pfus to about 1012pfus and is delivered by direct injection into a group of cancer cells or via intravenous injection.
REFERENCES:
patent: 3133861 (1964-05-01), Schwarz
patent: 4071618 (1978-01-01), Konobe et al.
patent: 4108983 (1978-08-01), Wallack
patent: 4211843 (1980-07-01), Dubreuil
patent: 4500512 (1985-02-01), Barme
patent: 4985244 (1991-01-01), Makino et al.
patent: 5001692 (1991-03-01), Farla et al.
patent: 5137727 (1992-08-01), Eckenhoff
patent: 5262359 (1993-11-01), Hierholzer
patent: 5304367 (1994-04-01), Biegon
patent: 5578448 (1996-11-01), Rota et al.
patent: 5713858 (1998-02-01), Heruth et al.
patent: 5738985 (1998-04-01), Miles et al.
patent: 5980508 (1999-11-01), Cardamone et al.
patent: 6012034 (2000-01-01), Hamparian et al.
patent: 6026316 (2000-02-01), Kucharczyk et al.
patent: 6083751 (2000-07-01), Feldhaus et al.
patent: 6095976 (2000-08-01), Nachtomy et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6896881 (2005-05-01), Russell et al.
patent: 7118740 (2006-10-01), Russell et al.
patent: 0 700 995 (2001-07-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 00/76450 (2000-12-01), None
U.S. Appl. No. 60/155,873, filed Sep. 29, 2005, Russell et al.
GenBank Accession No. U60282 dated Jul. 2, 1996, 2 pages.
Albonico et al., “Febrile infectious childhood diseases in the history of cancer patients and matched controls,”Medical Hypotheses, 1998, 51:315-320.
Alemany et al., “Replicative adenoviruses for cancer therapy,”Nat. Biotechnol., 2000, 18:723-727.
Andreansky et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,”Proc. Natl. Acad. Sci. USA, 1996, 93:11313-11318.
Arbit et al., “Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2in human brain tumors,”Eur. J. Nucl. Med., 1995, 22:419-426.
Asada, “Treatment of Human Cancer with Mumps Virus,”Cancer, 1974, 34:1907-1928.
Attenuvax®, Merck & Co., Inc., West Point, PA 19466, USA, Sep. 8, 2000.
Bae et al., “Genomic differences between the Diabetogenic and Nondiabetogenic Variants of Encephalomyocarditis Virus,”Virology, 1989, 170:282-287.
Bankamp et al., “Activity of Polymerase Proteins of Vaccine and Wild-Type Measles Virus Strains in a Minigenome Replication Assay,”J. Virol., 2002, 76(14):7073-7081.
Bateman et al., “Fusogenic Membrane Glycoproteins As a Novel Class of Genes for the Local and Immune-mediated Control of Tumor Growth,”Cancer Research, 2000, 60:1492-1497.
Bateman et al., [Correction to Cancer Research, 2000, 60:1492-1497] in “Announcements,”Cancer Research, 2000, 60:4975-4978.
Bateman et al., “Fusogenic Membrane Glycoproteins—A Novel Class of Cytotoxic Genes with Immunostimulatory Properties,”Gene Therapy, 1999, 6(Suppl. 1):S6, Abstract 24.
Bennett et al., “Fusion of Green Fluorescent Protein with the Zeocin™-Resistance Marker Allows Visual Screening and Drug Selection of Transfected Eukaryotic Cells,”Biotechniques, 1998, 24(3):478-482.
Berg et al., “Physiological functions of endosomal proteolysis,”Biochem. J., 1995, 307:313-326.
Bluming and Ziegler, “Regression of Burkitt's Lymphoma in Association with Measles Infection,”Lancet, 1971, 2:105-106.
Bolt and Pedersen, “The Role of Subtilisin-like Proprotein Convertases for Cleavage of the Measles Virus Fusion Glycoprotein in Different Cell Types,”Virology, 1998, 252:387-398.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 1990, 247(4948):1306-1310.
Cathomen et al. “A Matrix-less Measles Virus is Infectious and Elicits Extensive Cell Fusion: Consequences for Propagation in the Brain,” EMBO J., 1998, 17(14):3899-3909.
Cathomen et al., “Measles Viruses with Altered Envelope Protein Cytoplasmic Tails Gain Cell Fusion Competence,”J. Virol., 1998, 72(2):1224-1234.
Ch'ien et al., “Fatal Subacute Immunosuppressive Measles Encephalitis (SIME) in Children with Acute Lymphocytic Leukemia—Clinical, Electroencephalographic, and Computerized Tomographic Scan Features,”Clin. Electroencephalogr., 1983, 14(4):214-220.
Chambers et al., “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in ascidmouse model of human malignant glioma,”Proc. Natl. Acad. Sci. USA, 1995, 92:1411-1415.
Chisum et al.,Principles of Patent Law, 1998, Foundation Press, pp. 628-630.
Cohen et al., “Complete nucleotide sequence of an attenuated hepatitis A virus: Comparison with wild-type virus,”Proc. Natl. Acad. Sci. USA, 1987, 84:2497-2501.
Crawford et al., “Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography,”Eur. J. Nucl. Med., 1997, 24:1470-1478.
Dai et al., “Cloning and characterization of the thyroid iodide transporter,”Nature, 1996, 379:458-460.
de Felipe et al., “Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy,”Gene Therapy, 1999, 6:198-208.
de Swart et al., “Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype,”Lancet, 2000, 355:201-202.
Delassus et al., “Genetic Organization of Gibbon Ape Leukemia Virus,”Virology, 1989, 173:205-213.
Diaz et al., “A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy,”Gene Therapy, 2000, 7:1656-1663.
Dorig et al., “The human CD46 molecule is a receptor for measles virus (Edmonston strain),”Cell, 1993, 75(2):295-305.
Duechler et al., “Evolutionary relationships within the human rhinovirus genus: Comparison of serotypes 89, 2 and 14,”Proc. Natl. Acad. Sci. USA, 1987, 84:2605-2609.
Duprex et al., “Observation of Measles Virus Cell-to-Cell Spread in Astrocytoma Cells by Using a Green Fluorescent Protein-Expressing Recombinant Virus,”J. Virol., 1999, 73(11):9568-9575.
Earle et al., “The Complete Nucleotide Sequence of a Bovine Enterovirus,”J. Gen. Virol., 1988, 69:253-263.
Eiselein et al., “Treatment of Transplanted Murine Tumors with an Oncolytic Virus and Cyclophosphamide,”Cancer Res., 1978, 38:3817-3822.
Enders and Peebles, “Propagation in tissue cultures of cytopathogenic agents from patients with measles,”Proc. Soc. Exp. Biol. Med., 1954, 86(2):277-286.
Evermann and Burnstein, “Immune Enhancement of the Tumorigenicity of Hamster Brain Tumor Cells Persistently Infected with Measles Virus,”Int. J. Cancer, 1975, 16:861-869.
Flower et al., “Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy,”Eur. J. Nucl. Med., 1994, 21:531-536.
Flower et al., “Thyroid imaging using position emission tomography—a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicoss,”Br. J. Radiol., 1990, 63:325-330.
Fourrier et al., “Measles vaccination using Schwarz strain: clinical, serologic and electroencephalographic study,”Pediatrie, 1969, 24(1):97-98.
Galanis et al., “Use of Fusogenic Membrane Glycoproteins as Novel Therapeutic Transgenes in Gliomas,”Gene Therapy, 1999, 6(Suppl. 1):S7, Abstract 28.
Gambhir et al., “Assays for Noninvasive Imaging of Reporter Gene Expression,”Nucl. Med. Biol., 1999, 26:481-490.
Greenlee et al., “Cancer Statistics, 2000,”CA Cancer J. Clin., 2000, 50:7-33.
Greentree, “Hodgkin's Disease: Therapeutic Role of Measles Vaccine,
Fielding Adele
Grote Deanna
Peng Kah-Whye
Russell Stephen James
Fish & Richardson P.C.
Lucas Zachariah
Mayo Foundation for Medical Education and Research
LandOfFree
Method for limiting the growth of cancer cells using an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for limiting the growth of cancer cells using an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for limiting the growth of cancer cells using an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2745683